
Last updated: 2026-09-16 09:05:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Kura Oncology, Inc. (KURA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $11.26, with a market capitalisation of $1.03B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $7.36 to $13.90. This page covers its latest market performance, valuation, price trends and company information.
$1.03B | |
$11.52 | |
$43.00 | |
$2.50 | |
$11.30 | |
53.00 | |
1.80M | |
-- | |
$13.90 | |
$7.36 | |
-- | |
-- |
Kura Oncology, Inc. (KURA) is trading at $11.26 in pre-market trading as of 2026-09-16 08:57:00, down 0.39% ($0.04) from the previous close of $11.30
Pre-market trading shows how investors are pricing KURA before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Kura Oncology, Inc. (KURA) moved from $13.25 to $11.26, representing a decline of 15.05% ($1.99).
The stock traded between $11.03 and $13.27 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.75 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 59.6%
KURA is currently trading at $11.26, placing it 59.6% of the way from its 52-week low of $7.36 to its 52-week high of $13.90. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 260 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Kura Oncology, Inc. (KURA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.